Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
DanaherFRA:DAP +0.48%75 EV-to-EBIT is 31.73 as of Jul. 25, 2026, which is 4% above its 10-year median of 30.65. GuruFocus rates FRA:DAP with a GF Score™ of 75/100 and a GF Value™ of €210.98 (Modestly Undervalued). The stock has 5 warning signs investors should review. Among 104 Medical Diagnostics & Research companies, Danaher ranks worse than 68.27% on this metric.
EV-to-EBIT is calculated as Enterprise Value divided by its EBIT. As of today, Danaher's Enterprise Value is €137,868 Mil.
Danaher's EBIT for the trailing twelve months (TTM) ended in Jun. 2026 was €4,345 Mil. Therefore, Danaher's EV-to-EBIT for today is 31.73.
The historical rank and industry rank for Danaher's EV-to-EBIT or its related term are showing as below:
FRA:DAP'
s EV-to-EBIT Range Over the Past 10 Years
Min: 20.14 Med: 30.65 Max: 44.2
Current: 31.03
During the past 13 years, the highest EV-to-EBIT of Danaher was 44.20. The lowest was 20.14. And the median was 30.65.
FRA:DAP's EV-to-EBIT is ranked worse than 68.27% of 104
companies
in the Medical Diagnostics & Research industry
Industry Median: 22.565
vs FRA:DAP: 31.03
This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.
Danaher's Enterprise Value for the quarter that ended in Jun. 2026 was €136,637 Mil.
Danaher's EBIT for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was €4,345 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Danaher EV-to-EBIT Related Terms
Danaher EV-to-EBIT Historical Data
* Premium members only.
The historical data trend for Danaher's EV-to-EBIT can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Diagnostics & Research subindustry, Danaher's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Danaher EV-to-EBIT vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, Danaher's EV-to-EBIT distribution charts can be found below:
* The bar in red indicates where Danaher's EV-to-EBIT falls into.
Danaher's current Enterprise Value is €137,868 Mil.
Danaher's EBIT for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was €4,345 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Danaher (FRA:DAP) has a EV-to-EBIT of 31.73 as of Jul. 25, 2026. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on Danaher and its competitors. This is near median its historical median of 30.65. Over the past decade, Danaher's EV-to-EBIT has ranged from 20.14 to 44.20. According to the industry distribution chart, Danaher ranks #71 out of 104 companies in the Medical Diagnostics & Research industry, placing it in the top 68.3%.
Is Danaher's EV-to-EBIT too high?
Danaher's current EV-to-EBIT of 31.73 is near median its 10-year median of 30.65. Over the past 10 years, this metric has ranged from a low of 20.14 to a high of 44.20. The Medical Diagnostics & Research industry median EV-to-EBIT is 22.57. Danaher's value of 31.73 is 40.6% above this industry median. Based on the distribution chart, Danaher ranks #71 out of 104 companies in the Medical Diagnostics & Research industry, which is below the industry midpoint. Overall, Danaher has a GF Score™ of 75/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Danaher's EV-to-EBIT compare to TMO and IDXX?
According to the Medical Diagnostics & Research industry distribution chart, Danaher ranks #71 out of 104 companies for EV-to-EBIT. This places Danaher in the lower half of its industry. The industry median EV-to-EBIT is 22.57. Danaher's value of 31.73 is 40.6% above this benchmark. Historically, Danaher's own EV-to-EBIT has ranged from 20.14 to 44.20 over the past decade. While the company's 10-year median is 30.65 vs. the industry median of 22.57, Danaher has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBIT for a Medical Diagnostics & Research company?
The median EV-to-EBIT among Medical Diagnostics & Research companies is 22.57, based on 104 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBIT significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBIT should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Danaher's current EV-to-EBIT of 31.73 is 40.6% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBIT mean?
A high EV-to-EBIT can signal that a stock is expensive relative to its fundamentals. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on Danaher and its competitors. For the Medical Diagnostics & Research industry, the median EV-to-EBIT is 22.57 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Danaher's current EV-to-EBIT is 31.73, which is near median its own 10-year median of 30.65. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Danaher stock overvalued right now?
Based on GuruFocus' analysis, Danaher (FRA:DAP) is currently considered Modestly Undervalued. The stock's GF Value™ is €210.98, compared to a current price of €168.40 — trading 20.2% below its estimated fair value. The current EV-to-EBIT is 31.73, which is near median its 10-year median of 30.65 and 40.6% above the Medical Diagnostics & Research industry median of 22.57. Danaher's overall GF Score™ is 75/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBIT calculated?
EV-to-EBIT is calculated from a company's financial statements. For Danaher (FRA:DAP), the current EV-to-EBIT is 31.73 as of Jul. 25, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Danaher (FRA:DAP) Overvalued in 2026?
Based on GuruFocus' analysis, Danaher stock appears to be undervalued.
The current stock price of €168.40 is trading 20.2% below its estimated GF Value™ of €210.98.
GuruFocus considers Danaher to be Modestly Undervalued.
Key valuation signals for FRA:DAP:
EV-to-EBIT: 31.73 (near median its 10-year median of 30.65)
GF Value™: €210.98 vs. price of €168.40 (20.2% below fair value)
Industry Position: 40.6% above the Medical Diagnostics & Research median (#71 of 104)
No single metric tells the full story. See the FRA:DAP stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
In 1984, Danaher's founders transformed a real estate organization into an industrial-focused manufacturing company. Then, through a series of mergers, acquisitions, and divestitures, Danaher now focuses primarily on manufacturing scientific instruments and consumables in the life sciences and diagnostic industries after the late 2023 divestiture of its environmental and applied solutions group, Veralto.
75GF Score
Get the complete analysis for FRA:DAP
EV-to-EBIT is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:DAP has been successfully added to your 
